Focused Power Ultrasound Mediated Inferior Perirenal Adipose Tissue Modification Therapy for Essential Hypertension

Inclusion Criteria: 1. Individual has office systolic blood pressure (SBP) ≥ 140 mmHg and \<180 mmHg when receiving a medication regimen of one, two, or three antihypertensive medication classes； 2. Individual has 24-hour Ambulatory Blood Pressure Monitoring (ABPM) average SBP≥135 mmHg； 3. The anteroposterior, transverse and axial diameters of inferior perirenal fat pad measured by ultrasound should be at least 20mm； 4. Individual is willing to sign the informed consent of the study. Exclusion Criteria: 1. Individual is diagnosed as secondary hypertension (e.g. renal parenchymal hypertension, renal artery stenosis, primary aldosteronism, pheochromocytoma, Cushing's syndrome, aortic coarctation, obstructive sleep apnea hypopnea syndrome)； 2. Individual has history of kidney and or kidney surrounding tissue surgery; 3. Individuals has impairment of liver or kidney function (ALT, AST or creatinine is greater than 2 times of the upper limit of normal reference); 4. Individual has myocardial infarction, unstable angina pectoris, cerebrovascular accident or transient ischemic attack within 6 months of enrollment; 5. Individual has type 1 diabetes or poorly-controlled type 2 diabetes； 6. Individual has uncontrolled thyroid dysfunction; 7. Individual has urinary calculi and/or hematuria； 8. Individual has atrial fibrillation; 9. Individual has severe structural heart disease (e.g. heart valve disease, cardiomyopathy, congenital heart disease); 10. Individual has second degree and above atrioventricular block； 11. Individual has abnormal coagulation function; 12. Individual has infected waist skin; 13. Individual has malignant tumor; 14. Individual is pregnant, nursing or planning to be pregnant; 15. Individual is unwilling to sign informed consent; 16. Individual fails to complete the screening period.